Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
30 Julio 2024 - 5:26AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices a €1.4bn bond offering
30 July
2024 07:00 BST
AstraZeneca prices €1.4 billion bond offering
AstraZeneca
PLC (the Company) announces that, on 29 July 2024, its wholly owned
subsidiary AstraZeneca Finance LLC, successfully priced two
tranches of Eurobonds totalling €1.4 billion (the Offering).
The Offering is expected to close on 5 August 2024, subject to
customary closing conditions.
The
Offering consisted of the following notes, issued by AstraZeneca
Finance LLC and fully and unconditionally guaranteed by the
Company:
· €650
million of fixed rate notes with a coupon of 3.121% maturing on 5
August 2030; and
· €750
million of fixed rate notes with a coupon of 3.278% maturing on 5
August 2033 (together, the Notes).
The
Company expects to use the net proceeds of the offering for general
corporate purposes.
BNP
Paribas, Goldman Sachs International, Morgan Stanley and
Société Générale acted as joint book-running
managers on the transaction.
The
Notes will be issued under the US$10,000,000,000 EMTN programme of
the Company and AstraZeneca Finance LLC and admitted to listing on
the UK Financial Conduct Authority's Official List and to trading
on the London Stock Exchange's Main Market.
The
Notes have not been registered under the U.S. Securities Act of
1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from
registration.
This
announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes described herein, nor
shall there be any sale of these Notes in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca's innovative medicines are sold in more
than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For
details on how to contact the Investor Relations Team, please
click here. For Media
contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
30 July 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
AstraZeneca (NASDAQ:AZN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
